In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris — DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man Trial

Hector M. Garcia-Garcia* (Corresponding Author), Michael Haude, Kayode Kuku, Alexandre Hideo-Kajita, Hüseyin Ince, Alexandre Abizaid, Ralph Tölg, Pedro Alves Lemos, Clemens von Birgelen, Evald Høj Christiansen, William Wijns, Javier Escaned, Jouke Dijkstra, Ron Waksman

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

28 Citations (Scopus)

Abstract

Rationale: Bioresorbable scaffolds may confer clinical benefit in long-term studies; early mechanistic studies using intravascular imaging have provided insightful information about the immediate and mid-term local serial effects of BRS on the coronary vessel wall.

Objectives: We assessed baseline, 6- and 12-month imaging data of the drug-eluting absorbable metal scaffold (DREAMS 2G).

Methods and results: The international, first-in-man BIOSOLVE-II trial enrolled 123 patients with up to 2 de novo lesions (in vessels of 2.2 to 3.7 mm). Angiographic based vasomotion, curvature and angulation were assessed; intravascular ultrasound (IVUS) derived radiofrequency (RF) data analysis and echogenicity were evaluated; optical coherence tomography (OCT) attenuation and backscattering analysis were also performed. There was hardly any difference in curvature between pre-procedure and 12 months (− 0.0019; p = 0.48). The change in angulation from pre- to 12 months was negligible (− 3.58°; 95% CI [− 5.97, − 1.20]), but statistically significant. At 6 months, the change in QCA based minimum lumen diameter in response to high dose of acetylcholine and IVUS-RF necrotic core percentage showed an inverse relationship (estimate of − 0.489; p = 0.055) and with fibrous volume a positive relationship (estimate of 0.53, p = 0.035). Bioresorption analysis by OCT showed that the maximum attenuation values decreased significantly from post-procedure at 6 months (Δ 6 months vs. post-proc. is − 13.5 [95% CI − 14.6, − 12.4]) and at 12 months (Δ 12 months vs. post-proc. is − 14.0 [95% CI − 15.4, − 12.6]). By radiofrequency data, the percentage of dense calcium decreased significantly from post-procedure at 6 months and at 12 months. Likewise, by echogenicity, hyperechogenic structures decreased significantly from post-procedure at 6 months; thereafter, they remained unchanged.

Conclusion: Following implantation of DREAMS 2G, restoration of the vessel geometry, vasomotion and bioresorption signs were observed at up to 12 months; importantly, these changes occurred with preservation of the lumen size between 6 and 12 months. NCT01960504

Original languageEnglish
Pages (from-to)22-28
Number of pages7
JournalInternational journal of cardiology
Volume255
DOIs
Publication statusPublished - 15 Mar 2018

Keywords

  • UT-Hybrid-D
  • Coronary artery disease
  • DREAMS 2G
  • Magnesium scaffold
  • Metal scaffold
  • Sirolimus
  • Bioresorbable scaffold

Fingerprint Dive into the research topics of 'In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris — DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man Trial'. Together they form a unique fingerprint.

Cite this